Kaletra

You mentioned 3 of the one's I'm interested in, Kaletra is the 4th.

Antiretroviral Medications 2003

"Many patients living here in Mexico depend on access to drugs such as Kaletra that are available elsewhere at a much, much lower cost," said

Digital50.com Digital 50 Daily Industry News RSS Feed 2009

Sales of anti-HIV drug Kaletra declined 7% to $328 million.

Abbott Profit Falls 40% on Acquisition, Recall Costs Peter Loftus 2010

"The verdict affirms GSK's position that Abbott acted in bad faith and in breach of contract when it licensed promotional rights over Norvir and then raised its price for Norvir by 400% while maintaining the price for the company's ritonavir-containing fixed-dose combination, Kaletra."

Jury Finds Abbott Broke Glaxo Pact but Not Antitrust Laws Joan E. Solsman 2011

Combined sales of cholesterol drugs TriCor and Trilipix rose 15% to $291 million, while sales for HIV drug Kaletra were roughly flat at $292 million.

Abbott Labs' Earnings, Outlook Hurt By Health Overhaul 2010

Combined sales of cholesterol drugs TriCor and Trilipix were up 15.6% at $388 million, while HIV treatment Kaletra posted a 14.2% decline to $294 million for the quarter.

Abbott Posts Flat Earnings 2010

In addition to Latisse, the FDA went after Eli Lilly for a print ad misrepresenting its depression and pain drug Cymbalta; Abbott Laboratories for an upbeat DVD interview in which Earvin "Magic" Johnson suggests the HIV drug Kaletra is more effective than studies show; and GlaxoSmithKline for online ads marketing its migraine medication Treximet without sufficiently mentioning rare but potentially life-threatening side effects.

Ten Misleading Drug Ads Rebecca Ruiz 2010

One of the products for which Thailand issued a "compulsory license" -- an authorization of generic competition for a product that remains on patent -- was Kaletra, an important combination HIV/AIDS drug made by the Chicago drug giant Abbott Laboratories.

Robert Weissman: Ken Adelman's (New) Lies 2008

In the Jan. 3, 2007 issue of The Wall Street Journal, John Carreyrou discussed the company's strategy to increase revenues and stifle competition for Kaletra, its new AIDS therapy.

Lisa Conte: Big Pharma--Innovation in Business Models to Address Global Health Needs 2008

In 2007, he took another HIV/AIDS patent -- Abbott Laboratory's Kaletra -- and Sanofi-Aventis's patent for a heart drug, Plavix.

Bangkok's Drug War, Round Two 2008